Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Correction: Multiplex immunohi...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer

Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer

Bibliographic Details
Main Authors: Keren Jia, Yang Chen, Yu Sun, Yajie Hu, Lei Jiao, Jie Ma, Jiajia Yuan, Changsong Qi, Yanyan Li, Jifang Gong, Jing Gao, Xiaotian Zhang, Jian Li, Cheng Zhang, Lin Shen
Format: Article
Language:English
Published: BMC 2023-09-01
Series:BMC Medicine
Online Access:https://doi.org/10.1186/s12916-023-03090-4
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1186/s12916-023-03090-4

Similar Items

  • Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
    by: Keren Jia, et al.
    Published: (2022-07-01)
  • CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
    by: Canming Wang, et al.
    Published: (2023-08-01)
  • Multiplex immunohistochemistry defines two cholesterol metabolism patterns predicting immunotherapeutic outcomes in gastric cancer
    by: Wei Tang, et al.
    Published: (2023-12-01)
  • CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
    by: Xi Chen, et al.
    Published: (2023-06-01)
  • Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications
    by: Jinxia Chen, et al.
    Published: (2023-03-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs